Biogen (BIIB) Tops Q1 EPS by 30c, Updates Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $199.71 +1.59%
EPS Growth %: -41.3%
Financial Fact:
Net income attributable to Biogen Idec Inc.: 1.03B
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -41.3%
Financial Fact:
Net income attributable to Biogen Idec Inc.: 1.03B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q1 EPS of $5.34, $0.30 better than the analyst estimate of $5.04. Revenue for the quarter came in at $2.69 billion versus the consensus estimate of $2.65 billion.
GUIDANCE:
Biogen sees FY2021 EPS of $17.50-$19.00, versus the consensus of $18.41. Biogen sees FY2021 revenue of $10.45-10.75 billion, versus the consensus of $10.57 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- Ridgepost Capital acquires Stellus Capital Management for $4B AUM
- Sun Communities names Ileana McAlary as general counsel and EVP
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
